Literature DB >> 1697292

Radioimmunoimaging of tumors with radioactive antibody against a glycoprotein (GP68) found in developing mouse brain.

S Kojima1, A Awaya, M Ishido, Y Koyama, A Kubodera, Y Hashimoto, H Fukui, H Muramatsu, T Muramatsu.   

Abstract

The in vivo localization of a polyclonal antibody (pAb) against a glycoprotein with a molecular mass of 68 kDa (GP68), which was found in developing mouse brain, was studied in murine tumor models to evaluate potential applications of this antibody for in vivo radioimmunodetection and/or therapy of cancer. The tissue distribution of 125I-labeled GP68 pAb 3 days after i.v. injection into mice bearing four different kinds of solid tumor revealed a high uptake ratio by adenocarcinoma 755 and Lewis 3LL lung cancer. In contrast, the uptake ratio was low in mice bearing Ehrlich solid tumor and sarcoma-180 (S-180). These uptake ratios accorded well with the in vitro binding activity of this antibody with the tumor cells. In an immunoscintigraphic study, adenocarcinoma 755 was successfully visualized with 67Ga-labeled GP68 pAb. The results of these biodistribution and in vivo radioimmunoscintigraphic studies suggest that GP68 antibody may be applicable to the diagnosis and/or therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697292     DOI: 10.1007/bf01612915

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Localization of radioiodinated antibody to alpha-fetoprotein in hepatoma transplanted in rats and a case report of alpha-fetoprotein antibody treatment of a hepatoma patient.

Authors:  T Koji; N Ishii; T Munehisa; Y Kusumoto; S Nakamura; A Tamenishi; A Hara; K Kobayashi; Y Tsukada; S Nishi; H Hirai
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

2.  Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-fetoprotein.

Authors:  H Sakahara; K Endo; T Nakashima; M Koizumi; H Ohta; K Torizuka; T Furukawa; Y Ohmomo; A Yokoyama; K Okada
Journal:  J Nucl Med       Date:  1985-07       Impact factor: 10.057

3.  [Experimental studies on the tumor imaging using antibodies to human alpha-fetoprotein. 1. Fluctuations in the iodine-labeled antibody activities].

Authors:  H Sakahara; K Endo; T Nakashima; H Ohta; K Torizuka; K Okada; O Yoshida; H Hirai
Journal:  Kaku Igaku       Date:  1984-07

4.  Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m.

Authors:  R L Childs; D J Hnatowich
Journal:  J Nucl Med       Date:  1985-03       Impact factor: 10.057

5.  Stage-specific polypeptides in the developing mouse brain as demonstrated by two-dimensional gel electrophoresis.

Authors:  S Noguchi; S Ogata; M Sato; T Muramatsu
Journal:  J Biochem       Date:  1984-09       Impact factor: 3.387

6.  Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen.

Authors:  D M Goldenberg; E E Kim; F H DeLand; S Bennett; F J Primus
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

7.  Radioimmunodetection of human pancreatic tumor xenografts using DU-PAN II monoclonal antibody.

Authors:  K Nakamura; A Kubo; S Hashimoto; T Furuuchi; H Takami; O Abe
Journal:  Ann Nucl Med       Date:  1988-05       Impact factor: 2.668

8.  Comparisons of labeling efficiency, biological activity and biodistribution among 125I-, 67Ga-DTPA-and 67Ga-DFO-lectins.

Authors:  S Kojima; M Jay
Journal:  Eur J Nucl Med       Date:  1987

9.  Radioimmunodetection of cancer with radiolabeled antibodies to alpha-fetoprotein.

Authors:  E E Kim; F H DeLand; M O Nelson; S Bennett; G Simmons; E Alpert; D M Goldenberg
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

10.  Immunological considerations in the use of goat antibodies to carcinoembryonic antigen for the radioimmunodetection of cancer.

Authors:  F J Primus; D M Goldenberg
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.